Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000953960 | SCV001100561 | benign | not provided | 2023-11-03 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000953960 | SCV001802530 | likely benign | not provided | 2021-06-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004029855 | SCV003547868 | uncertain significance | not specified | 2021-04-29 | criteria provided, single submitter | clinical testing | The c.265C>T (p.H89Y) alteration is located in exon 3 (coding exon 2) of the KIAA2022 gene. This alteration results from a C to T substitution at nucleotide position 265, causing the histidine (H) at amino acid position 89 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV000953960 | SCV005210630 | likely benign | not provided | criteria provided, single submitter | not provided |